Deep Track Capital, LP
- SEC CIK
- 0001856083
- Latest filing
- Aug 14, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 65
- −4 vs. Q1 2025
- Portfolio value
- $3.11B
- +$22.3M (+0.7%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GHGuardant Health, Inc. | COM | 4,250,000 | $221.2M | 7.1% | −1,193,721−21.9% | Reduced | History |
| IONSIonis Pharmaceuticals Inc | COM | 4,891,544 | $193.3M | 6.2% | +327,337+7.2% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 3,245,899 | $179.4M | 5.8% | +245,899+8.2% | Added | History |
| DVAXDynavax Technologies Corp | COM NEW | 17,791,486 | $176.5M | 5.7% | 00.0% | Unchanged | History |
| INSMINSMED Inc | COM PAR $.01 | 1,750,000 | $176.1M | 5.7% | +1,495,249+586.9% | Added | History |
| AKROAkero Therapeutics, Inc. | COM | 3,042,598 | $162.4M | 5.2% | −167,672−5.2% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 9,500,000 | $152.0M | 4.9% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 14,294,420 | $132.7M | 4.3% | 00.0% | Unchanged | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 7,000,000 | $121.2M | 3.9% | +2,000,000+40.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 3,650,000 | $120.6M | 3.9% | +576,147+18.7% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 5,133,917 | $106.5M | 3.4% | +1,033,917+25.2% | Added | History |
| ETNB89bio, Inc. | COM | 9,500,000 | $93.3M | 3.0% | +183,667+2.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 801,371 | $83.7M | 2.7% | +801,371 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 5,380,449 | $75.2M | 2.4% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,750,000 | $70.9M | 2.3% | +265,734+17.9% | Added | History |
| PCVXVaxcyte, Inc. | COM | 2,150,000 | $69.9M | 2.2% | +1,400,000+186.7% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 6,064,910 | $69.1M | 2.2% | +564,910+10.3% | Added | History |
| GERNGeron Corp | COM | 43,000,000 | $60.6M | 1.9% | +4,823,749+12.6% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 1,800,000 | $56.5M | 1.8% | +388,598+27.5% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 1,350,000 | $49.1M | 1.6% | 00.0% | Unchanged | History |
| MAZEMaze Therapeutics, Inc. | COM | 3,948,910 | $48.5M | 1.6% | +679,784+20.8% | Added | History |
| ANIPAni Pharmaceuticals Inc | COM | 700,000 | $45.7M | 1.5% | 00.0% | Unchanged | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,350,000 | $42.3M | 1.4% | +350,000+35.0% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,233,148 | $41.6M | 1.3% | −124,554−5.3% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 2,000,000 | $40.7M | 1.3% | 00.0% | Unchanged | History |
| BBIOBridgeBio Pharma, Inc. | COM | 900,000 | $38.9M | 1.2% | −1,900,000−67.9% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 16,852,147 | $38.4M | 1.2% | −997,335−5.6% | Reduced | History |
| MTSRMetsera, Inc. | COM | 1,094,408 | $31.1M | 1.0% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 7,495,000 | $28.0M | 0.9% | +1,918,442+34.4% | Added | History |
| TECXTectonic Therapeutic, Inc. | COM | 1,401,938 | $27.9M | 0.9% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 3,480,144 | $26.6M | 0.9% | −99,065−2.8% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM NEW | 2,509,301 | $25.1M | 0.8% | +2,509,301 | New | History |
| MBXMBX Biosciences, Inc. | COM | 2,188,592 | $25.0M | 0.8% | −830,343−27.5% | Reduced | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 8,831,007 | $24.7M | 0.8% | −28,641−0.3% | Reduced | History |
| GHRSGH Research PLC | ORDINARY SHARES | 2,000,000 | $24.4M | 0.8% | 00.0% | Unchanged | History |
| BCAXBicara Therapeutics Inc. | COM | 2,426,657 | $22.5M | 0.7% | +426,657+21.3% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 1,918,798 | $21.5M | 0.7% | +474,089+32.8% | Added | History |
| ENGNenGene Therapeutics Inc. | COM | 4,557,575 | $16.6M | 0.5% | 00.0% | Unchanged | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 2,500,000 | $16.2M | 0.5% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 1,442,767 | $15.8M | 0.5% | −856,800−37.3% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 3,442,833 | $14.7M | 0.5% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 275,000 | $14.5M | 0.5% | +275,000 | New | History |
| HELPCybin Inc. | COM NEW | 1,529,987 | $12.8M | 0.4% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 250,000 | $12.2M | 0.4% | +250,000 | New | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 1,203,244 | $8.36M | 0.3% | +436,228+56.9% | Added | History |
| CBIOCrescent Biopharma, Inc. | COM | 453,686 | $7.32M | 0.2% | +453,686 | New | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 500,000 | $6.57M | 0.2% | +500,000 | New | History |
| NVAXNovavax Inc | COM NEW | 998,542 | $6.29M | 0.2% | −519,640−34.2% | Reduced | History |
| IVVDInvivyd, Inc. | COM | 8,585,980 | $6.14M | 0.2% | −1,136,274−11.7% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM NEW | 751,422 | $6.01M | 0.2% | +751,422 | New | History |
| CNTXContext Therapeutics Inc. | COM | 7,419,355 | $4.86M | 0.2% | 00.0% | Unchanged | History |
| PLRXPliant Therapeutics, Inc. | COM | 3,947,807 | $4.58M | 0.1% | −1,451,874−26.9% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 259,800 | $4.44M | 0.1% | −639,931−71.1% | Reduced | History |
| XNCRXencor Inc | COM | 549,439 | $4.32M | 0.1% | 00.0% | Unchanged | History |
| INOInovio Pharmaceuticals, Inc. | COM SHS | 1,981,370 | $4.03M | 0.1% | −1,137,792−36.5% | Reduced | History |
| KRROKorro Bio, Inc. | COM | 277,966 | $3.47M | 0.1% | −596,648−68.2% | Reduced | History |
| IMAImageneBio, Inc. | COM | 2,515,513 | $3.37M | 0.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 219,015 | $3.28M | 0.1% | 00.0% | Unchanged | History |
| ALGSAligos Therapeutics, Inc. | COM NEW | 444,110 | $3.20M | 0.1% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 567,103 | $2.83M | 0.1% | −292,773−34.0% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 1,727,562 | $1.81M | 0.1% | −1,556,221−47.4% | Reduced | History |
| CLYMClimb Bio, Inc. | COM | 1,040,115 | $1.29M | <0.1% | 00.0% | Unchanged | History |
| SEPNSepterna, Inc. | COM | 121,716 | $1.29M | <0.1% | −1,791,213−93.6% | Reduced | History |
| RAPPRapport Therapeutics, Inc. | COM | 98,237 | $1.12M | <0.1% | −359,319−78.5% | Reduced | History |
| OKUROnKure Therapeutics, Inc. | COM CL A | 180,510 | $431.4K | <0.1% | −343,479−65.6% | Reduced | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SRPTSarepta Therapeutics, Inc. | COM | $7.70M | – |
Sold out since Q1 2025 (11)
Positions held at the end of Q1 2025 that are gone from this filing.
| Security | Class | Shares in Q1 2025 | Value in Q1 2025 | % of portfolio in Q1 2025 | History |
|---|---|---|---|---|---|
| ITCIIntra-Cellular Therapies, Inc. | COM | 2,000,000 | $263.8M | 8.5% | History |
| AMGNAmgen Inc | Stock | 113,035 | $35.2M | 1.1% | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,400,000 | $30.8M | 1.0% | History |
| DYNDyne Therapeutics, Inc. | COM | 2,000,000 | $20.9M | 0.7% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 741,068 | $18.6M | 0.6% | History |
| SAGESage Therapeutics, Inc. | COM | 2,038,845 | $16.2M | 0.5% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 6,011,380 | $7.33M | 0.2% | History |
| BEAMBeam Therapeutics Inc. | COM | 315,765 | $6.17M | 0.2% | History |
| RGLSRegulus Therapeutics Inc. | COM | 3,262,564 | $5.71M | 0.2% | History |
| ALLKAllakos Inc. | COM | 7,232,701 | $1.65M | 0.1% | History |
| NGNENeurogene Inc. | COM | 116,660 | $1.37M | <0.1% | History |